
Reliferon 3MIU Injection
Marketer
Reliance Life Sciences
Salt Composition
Interferon Alpha 2B (3miu)
Overview Reliferon 3MIU Injection
Hepatitis B and C, multiple myeloma, follicular lymphoma, and hairy cell leukemia are treated with the injectable medication, Reliferon 3MIU. Administration is strictly by a healthcare professional via injection, and the prescribed dosage must be followed precisely. Treatment duration is individualized, depending on patient response. Discontinuation should only occur under physician guidance; premature cessation may be detrimental. While benefits may not be immediately apparent (taking several weeks or months), consistent use is crucial. Common side effects include headache, nausea, vomiting, dizziness, and sleep disturbances. A reduction in blood cell count, increasing infection risk, is possible. Report fever, chills, breathing difficulties, unusual bleeding/bruising, or dark urine immediately. Regular blood tests monitoring blood cell counts, thyroid function, liver and kidney health, and electrolyte levels are essential. Pre-existing liver or kidney disease, mental health conditions (including depression, mood changes, suicidal ideation), or vision problems must be disclosed before treatment initiation as Reliferon 3MIU can exacerbate these issues. Inform your doctor of all other medications being taken due to potential interactions. Reliferon 3MIU is contraindicated during pregnancy and breastfeeding; reliable contraception for both partners is mandatory throughout treatment.
Uses of Reliferon 3MIU Injection
Long-term hepatitis B (HBV) or C (HCV) infections, multiple myeloma, follicular lymphoma, and hairy cell leukemia.
Major Benefits of Reliferon 3MIU Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Reliferon 3MIU Injection:
- Headache
- Dizziness
- Blurred vision
- Insomnia (difficulty in sleeping)
- Vomiting
- Nausea
- Dryness in mouth
- Abdominal pain
- Agitation
- Sore throat
- Decreased white blood cell count
- Viral infection
- Indigestion
- Fatigue
- Fever
- Anxiety
- Depression
- Decreased appetite
- Cough
- Impaired concentration
- Nervousness
- Stomatitis (Inflammation of the mouth)
How to use Reliferon 3MIU Injection:
Administering this medication will be handled by your physician or their assistant; please do not attempt self-medication.
How Reliferon 3MIU Injection works:
Immunomodulation is achieved through Reliferon 3MIU Injection.
SAFETY ADVICE
AlcoholUNSAFE
Alcohol and Reliferon 3MIU Injection should not be used together due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
The use of Reliferon 3MIU Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingSAFE IF PRESCRIBED
Administration of Reliferon 3MIU Injection while breastfeeding appears to pose minimal risk. Available human data indicate negligible infant harm.
DrivingUNSAFE
Administering Reliferon 3MIU Injection might reduce attentiveness, impair visual acuity, or induce drowsiness and dizziness. Driving should be avoided if such effects manifest.
KidneyUNSAFE
The use of Reliferon 3MIU Injection is likely inadvisable for individuals with kidney disease and should be avoided. A physician's consultation is recommended. Patients exhibiting renal dysfunction require careful consideration before administration.
LiverCAUTION
Individuals with significant hepatic impairment should use Reliferon 3MIU Injection cautiously. Dosage modification of Reliferon 3MIU Injection might be necessary. Physician consultation is recommended.
What if you forget to take Reliferon 3MIU Injection :
Should you forget a Reliferon 3MIU Injection, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Reliferon 3MIU Injection
| Label | Value |
|---|---|
| Chemical Category | Interferon proteins |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Behavior Class | Interferon proteins |
